Cord Blood Hematopoietic Cell Transplantation

Hal Broxmeyer, Sherif Farag, Vanderson Rocha

Research output: Chapter in Book/Report/Conference proceedingChapter

11 Citations (Scopus)

Abstract

Cord blood (CB) hematopoietic cell transplantation (HCT) has advanced greatly since the first transplant performed in October 1988. As of 2012, there have been over 30,000 CB transplants done for a wide variety of malignant and non-malignant disorders, most of which were performed with partially HLA-matched unrelated CB cells. Advantages of CB, compared to other stem cell sources, include readily available HLA-typed CB and a more forgiving nature in using partially HLA-mismatched cells. However, time to neutrophil, platelet, and immune cell recovery is slower. We provide a historical perspective on CB HCT, and detail the status of CB banking, clinical results, biology and immunology, and means to manipulate donor CB cells for efficacious engraftment and treatment. The status of other cells in CB that may have implications for regenerative medicine, is discussed.

Original languageEnglish (US)
Title of host publicationThomas' Hematopoietic Cell Transplantation: Fifth Edition
PublisherWiley Blackwell
Pages437-455
Number of pages19
Volume1-2
ISBN (Electronic)9781118416426
ISBN (Print)9781118416006
DOIs
StatePublished - Jan 1 2016

Fingerprint

Cell Transplantation
Fetal Blood
Blood Cells
Transplants
Blood Banks
Regenerative Medicine
Allergy and Immunology
Neutrophils
Stem Cells
Blood Platelets

Keywords

  • Children and adults
  • Cord blood banking
  • Cord blood donor search
  • Cord blood hematopoietic stem and progenitor cells
  • Engraftment
  • Immune reconstitution
  • Malignant hematologic disorders
  • Non-malignant hematologic and genetic disorders
  • Related cord blood hematopoietic cell transplantation
  • Unrelated cord blood hematopoietic cell transplantation

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Broxmeyer, H., Farag, S., & Rocha, V. (2016). Cord Blood Hematopoietic Cell Transplantation. In Thomas' Hematopoietic Cell Transplantation: Fifth Edition (Vol. 1-2, pp. 437-455). Wiley Blackwell. https://doi.org/10.1002/9781118416426.ch39

Cord Blood Hematopoietic Cell Transplantation. / Broxmeyer, Hal; Farag, Sherif; Rocha, Vanderson.

Thomas' Hematopoietic Cell Transplantation: Fifth Edition. Vol. 1-2 Wiley Blackwell, 2016. p. 437-455.

Research output: Chapter in Book/Report/Conference proceedingChapter

Broxmeyer, H, Farag, S & Rocha, V 2016, Cord Blood Hematopoietic Cell Transplantation. in Thomas' Hematopoietic Cell Transplantation: Fifth Edition. vol. 1-2, Wiley Blackwell, pp. 437-455. https://doi.org/10.1002/9781118416426.ch39
Broxmeyer H, Farag S, Rocha V. Cord Blood Hematopoietic Cell Transplantation. In Thomas' Hematopoietic Cell Transplantation: Fifth Edition. Vol. 1-2. Wiley Blackwell. 2016. p. 437-455 https://doi.org/10.1002/9781118416426.ch39
Broxmeyer, Hal ; Farag, Sherif ; Rocha, Vanderson. / Cord Blood Hematopoietic Cell Transplantation. Thomas' Hematopoietic Cell Transplantation: Fifth Edition. Vol. 1-2 Wiley Blackwell, 2016. pp. 437-455
@inbook{5e5c51ec024f4a18b4b845db7a667d1c,
title = "Cord Blood Hematopoietic Cell Transplantation",
abstract = "Cord blood (CB) hematopoietic cell transplantation (HCT) has advanced greatly since the first transplant performed in October 1988. As of 2012, there have been over 30,000 CB transplants done for a wide variety of malignant and non-malignant disorders, most of which were performed with partially HLA-matched unrelated CB cells. Advantages of CB, compared to other stem cell sources, include readily available HLA-typed CB and a more forgiving nature in using partially HLA-mismatched cells. However, time to neutrophil, platelet, and immune cell recovery is slower. We provide a historical perspective on CB HCT, and detail the status of CB banking, clinical results, biology and immunology, and means to manipulate donor CB cells for efficacious engraftment and treatment. The status of other cells in CB that may have implications for regenerative medicine, is discussed.",
keywords = "Children and adults, Cord blood banking, Cord blood donor search, Cord blood hematopoietic stem and progenitor cells, Engraftment, Immune reconstitution, Malignant hematologic disorders, Non-malignant hematologic and genetic disorders, Related cord blood hematopoietic cell transplantation, Unrelated cord blood hematopoietic cell transplantation",
author = "Hal Broxmeyer and Sherif Farag and Vanderson Rocha",
year = "2016",
month = "1",
day = "1",
doi = "10.1002/9781118416426.ch39",
language = "English (US)",
isbn = "9781118416006",
volume = "1-2",
pages = "437--455",
booktitle = "Thomas' Hematopoietic Cell Transplantation: Fifth Edition",
publisher = "Wiley Blackwell",

}

TY - CHAP

T1 - Cord Blood Hematopoietic Cell Transplantation

AU - Broxmeyer, Hal

AU - Farag, Sherif

AU - Rocha, Vanderson

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Cord blood (CB) hematopoietic cell transplantation (HCT) has advanced greatly since the first transplant performed in October 1988. As of 2012, there have been over 30,000 CB transplants done for a wide variety of malignant and non-malignant disorders, most of which were performed with partially HLA-matched unrelated CB cells. Advantages of CB, compared to other stem cell sources, include readily available HLA-typed CB and a more forgiving nature in using partially HLA-mismatched cells. However, time to neutrophil, platelet, and immune cell recovery is slower. We provide a historical perspective on CB HCT, and detail the status of CB banking, clinical results, biology and immunology, and means to manipulate donor CB cells for efficacious engraftment and treatment. The status of other cells in CB that may have implications for regenerative medicine, is discussed.

AB - Cord blood (CB) hematopoietic cell transplantation (HCT) has advanced greatly since the first transplant performed in October 1988. As of 2012, there have been over 30,000 CB transplants done for a wide variety of malignant and non-malignant disorders, most of which were performed with partially HLA-matched unrelated CB cells. Advantages of CB, compared to other stem cell sources, include readily available HLA-typed CB and a more forgiving nature in using partially HLA-mismatched cells. However, time to neutrophil, platelet, and immune cell recovery is slower. We provide a historical perspective on CB HCT, and detail the status of CB banking, clinical results, biology and immunology, and means to manipulate donor CB cells for efficacious engraftment and treatment. The status of other cells in CB that may have implications for regenerative medicine, is discussed.

KW - Children and adults

KW - Cord blood banking

KW - Cord blood donor search

KW - Cord blood hematopoietic stem and progenitor cells

KW - Engraftment

KW - Immune reconstitution

KW - Malignant hematologic disorders

KW - Non-malignant hematologic and genetic disorders

KW - Related cord blood hematopoietic cell transplantation

KW - Unrelated cord blood hematopoietic cell transplantation

UR - http://www.scopus.com/inward/record.url?scp=84979947147&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84979947147&partnerID=8YFLogxK

U2 - 10.1002/9781118416426.ch39

DO - 10.1002/9781118416426.ch39

M3 - Chapter

AN - SCOPUS:84979947147

SN - 9781118416006

VL - 1-2

SP - 437

EP - 455

BT - Thomas' Hematopoietic Cell Transplantation: Fifth Edition

PB - Wiley Blackwell

ER -